Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PT Sinkona Indonesia Lestari is a prominent Indonesian pharmaceutical company specializing in the production of Quinine and its various salt derivatives from Cinchona bark. Established in 1986 as a joint venture between PT Kimia Farma and PT Perkebunan Nusantara VIII, the company operates a specialized manufacturing facility in Subang, West Java. It is one of the world's leading suppliers of high-purity Quinine Active Pharmaceutical Ingredients (APIs), including Quinine Sulfate, Quinine Hydrochloride, and Quinine Bisulfate. Beyond medicinal applications for treating malaria and muscle cramps, the company provides quinine products for the food and beverage industry, notably for use in tonic water. The company maintains international quality standards, holding certifications for Good Manufacturing Practices (GMP), ISO, Halal, and Kosher.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PT Sinkona Indonesia Lestari.